Compare CTGO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTGO | LUNG |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Industrial Specialties |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.6M | 57.9M |
| IPO Year | 2010 | 2020 |
| Metric | CTGO | LUNG |
|---|---|---|
| Price | $18.61 | $1.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $41.00 | $5.38 |
| AVG Volume (30 Days) | 386.4K | ★ 416.2K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.77 | 7.64 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $16.37 | $1.13 |
| 52 Week High | $34.38 | $3.88 |
| Indicator | CTGO | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 61.22 |
| Support Level | $16.37 | $1.53 |
| Resistance Level | $26.42 | $1.64 |
| Average True Range (ATR) | 1.27 | 0.11 |
| MACD | -0.37 | 0.01 |
| Stochastic Oscillator | 12.15 | 80.65 |
Contango Ore Inc operates in the United States. The company is engaged in the exploration of gold, silver, and copper ores in the State of Alaska. The company's focus is the exploration of a mineral lease with the Native Village of Tetlin whose governmental entity is the Tetlin Tribal Council for the exploration of minerals near Tok, Alaska. It has formed a joint venture to advance exploration of the Tetlin Property, which is prospective for gold and associated minerals. The Peak Gold JV Property is located in the Tetlin Hills and Mentasta Mountains of eastern interior Alaska. Its exploration projects are Lucky Shot, Johnson Tract, Eagle, Hona, Shamrock, and Triple Z.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.